MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

MammaPrint® (MP) is a 70‐gene signature that stratifies early‐stage breast cancer patients into low‐ and high risk of distant relapse. Further stratification of MP risk results identifies four risk subgroups, ultra‐low (UL), low, high 1, and high 2, with specific prognostic and predictive outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Haan, Josien C., Bhaskaran, Rajith, Ellappalayam, Architha, Bijl, Yannick, Griffioen, Christian J., Lujinovic, Ersan, Audeh, William M., Penault‐Llorca, Frédérique, Mittempergher, Lorenza, Glas, Annuska M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299843/
https://www.ncbi.nlm.nih.gov/pubmed/34841595
http://dx.doi.org/10.1002/gcc.23014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299843/
https://www.ncbi.nlm.nih.gov/pubmed/34841595
http://dx.doi.org/10.1002/gcc.23014

Ejemplares similares